微泡
人乳头瘤病毒
液体活检
基底细胞
癌症研究
活检
医学
病理
肿瘤科
内科学
生物
癌症
小RNA
基因
生物化学
作者
Michael M. Allevato,Joshua D. Smith,Michael Brenner,Steven B. Chinn
出处
期刊:The cancer journal
[Lippincott Williams & Wilkins]
日期:2023-07-01
卷期号:29 (4): 230-237
被引量:7
标识
DOI:10.1097/ppo.0000000000000671
摘要
ABSTRACT: The global incidence of human papillomavirus-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) has surged in recent decades, with HPV+ HNSCC accounting for >70% of oropharynx cancers in the United States. Its incidence in men has surpassed that of HPV+ cervical cancer in women, and reliable assays are needed for early detection and to monitor response to therapy. Human papillomavirus-positive OPSCC has a more favorable response to therapy and prognosis than HPV-negative (HPV-) HNSCC, motivating regimens to deintensify curative surgery or chemoradiotherapy protocols. A barrier to deintensifying and personalizing therapy is lack of reliable predictive biomarkers. Furthermore, HPV- HNSCC survival rates are static without reliable surveillance biomarkers available. The emergence of circulating plasma-based biomarkers reflecting the tumor-immune microenvironment heralds a new era in HNSCC diagnosis and therapy. We review evidence on tumor-derived extracellular vesicles (exosomes) as biomarkers for diagnosis, prognostication, and treatment in HPV+ and HPV- HNSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI